AA
SCMP

ALPS Advisors’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

ALPS Advisors’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-51,679
Closed -$928K – 1046
2017
Q4 		$928K Buy
51,679
+5,832
+13% +$71.8K 0.01% 277
2017
Q3 		$541K Buy
45,847
+3,907
+9% +$43.8K ﹤0.01% 380
2017
Q2 		$440K Buy
41,940
+2,507
+6% +$25.6K ﹤0.01% 626
2017
Q1 		$434K Sell
39,433
-4,614
-10% -$53.6K ﹤0.01% 656
2016
Q4 		$597K Sell
44,047
-14,368
-25% -$200K ﹤0.01% 277
2016
Q3 		$719K Sell
58,415
-41,786
-42% -$492K 0.01% 240
2016
Q2 		$1.1M Buy
100,201
+10,723
+12% +$120K 0.01% 205
2016
Q1 		$978K Buy
89,478
+11,092
+14% +$140K 0.01% 188
2015
Q4 		$1.35M Sell
78,386
-11,120
-12% -$199K 0.01% 201
2015
Q3 		$17.8K Buy
89,506
+14,322
+19% +$328K 0.02% 177
2015
Q2 		$1.24M Buy
75,184
+23,296
+45% +$404K 0.01% 200
2015
Q1 		$807K Buy
+51,888
New +$804K 0.01% 194

Other funds holding SCMP

GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AIM
Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

ALPS Advisors's SCMP Position: Q1 2018 in Review

ALPS Advisors sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 51,679 shares — an estimated $928K sold.

ALPS Advisors first reported a position in SCMP in Q1 2015 and held it in 12 quarters. The position peaked at $1.35M in Q4 2015. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

  • ALPS Advisors reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • ALPS Advisors sold 51,679 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $928K.
  • ALPS Advisors first reported a position in Sucampo Pharmaceuticals, Inc. in Q1 2015 and held it in 12 quarters.
  • ALPS Advisors's Sucampo Pharmaceuticals, Inc. position peaked at $1.35M in Q4 2015.
  • 3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.

Based on ALPS Advisors's 13F filing for Q1 2018, filed 1 May 2018.